Adverse Event Reporting News - Acorda Therapeutics announces changes to Zanaflex label
April 23, 2007 -- Acorda Therapeutics and FDA informed healthcare professionals on April 13 of changes to the Contraindications and Warnings Sections of the product...
Business Wire - Acorda Therapeutics Announces Receipt of ANDA Filing for Zanaflex Capsules
September 6, 2007 -- HAWTHORNE, N.Y. -- Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced today that it has received a Paragraph IV Certification Notice from Apotex Inc....
Business Wire - Acorda Therapeutics Announces Completion of Zanaflex Capsules™ Sales Force Expansion
January 8, 2007 -- HAWTHORNE, N.Y. -- Acorda Therapeutics, Inc.([R]) (Nasdaq: ACOR) reported today that it has completed the previously announced expansion of its sales...
Business Wire - Acorda Therapeutics Announces Expansion of Zanaflex Capsules™ Sales Force to 65
October 17, 2006 -- HAWTHORNE, N.Y. -- Acorda Therapeutics (Nasdaq: ACOR) announced today that it will expand its sales force to 65 people, including 52 area business...
Business Wire - Acorda Therapeutics Files Lawsuit Against Apotex Corp. and Apotex Inc. Relating to Zanaflex Capsules
October 11, 2007 -- HAWTHORNE, N.Y. -- Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced today that it has filed a lawsuit against Apotex Corp. and Apotex Inc. in the...
Business Wire - NovaDel Announces Positive Data from Pilot Pharmacokinetic Study Comparing Tizanidine Oral Spray to Zanaflex® Tablets
April 7, 2008 -- Oral Spray Technology Yields Significantly Greater Bioavailability FLEMINGTON, N.J. -- NovaDel Pharma Inc. (AMEX: NVD), a specialty pharmaceutical...
Business Wire - Acorda Therapeutics® Announces Completion of Enrollment in Fampridine-SR Clinical Trial in Multiple Sclerosis and Expansion of Sales Force for Zanaflex...
March 3, 2006 -- HAWTHORNE, N.Y. -- Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced today it has completed enrollment of its Phase 3 clinical trial of...
Business Wire - Acorda Therapeutics Reports Second Quarter 2008 Financial Results
August 5, 2008 -- HAWTHORNE, N.Y. -- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced its financial results for the second quarter of 2008.
Business Wire - Acorda Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results
February 11, 2008 -- * Lead clinical product, Fampridine-SR, entered and completed enrollment for second Phase 3 clinical trial in multiple sclerosis (MS); data expected...
Business Wire - Acorda Therapeutics Reports First Quarter 2008 Financial Results
May 5, 2008 -- HAWTHORNE, N.Y. -- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced its financial results for the first quarter 2008. "Acorda made...
